

Health Disparities in Hematologic Malignancies: From Genes to Outreach

Weill Cornell Medicine; Belfer Auditorium

June 6-7, 2025

Day 1 - Friday June 6, 2025

7:30 am	Registration and Breakfast:
8:00 am	Opening remarks • 8:05 Esther N. Mune, Ph.D. Lymphoma survivor- Emory, Atlanta <i>(10 min presentation + 5 min questions)</i>
8:20- 10:05 am	Session 1: The impact of germline variants and genomic abnormalities • 8:20 Catherine Marinac, Ph.D. Dana Farber Cancer Institute, Boston, MA <i>SUZC MM Dream team (Online study GWAS)</i> • 8:35 Lyndon Mitnaul, Ph.D. Regeneron Pharmaceuticals, Inc., Tarrytown, New York <i>Together 4 Change Genomics and Equity Initiative.</i> • 8:50 Maureen Murphy, Ph.D. Wistar Institute, Philadelphia, PA <i>Germline variants (p53, HSP) in AA patients</i> • 9:05 Discussion leader: Michelle Hildebrandt, Ph.D. The University of Texas, MD Anderson Cancer Center <i>(45 min call to action-discussion)</i>
9:50 -10:15 am	Coffee Break
10:15-11:45 pm	Session 2: Prognostic and therapeutic implications of the molecular landscape- Part A • 10:15 Aaron Viny, M.D. Columbia University, New York, NY <i>Hispanic patients with new molecular variant of leukemia.</i> • 10:30 Wendy Cozen, D.O. University of California, Irvine, CA <i>HL and MM in AA patients</i> • 10:45 Sandeep Dave, M.D. Duke University, Durham, NC <i>Genetic origins of adverse outcomes in African Americans with lymphoma</i> • 11:00 Rosalie Griffin Ph.D. The University of Texas, MD Anderson Cancer Center <i>Genetic origins of lymphoma and CLL in minorities</i>

<ul style="list-style-type: none"> 11:15 	<p>Discussion leader: Wendy Cozen, D.O. University of California, Irvine, CA (30 min call to action-discussion)</p>
11:45 pm	Lunch
1:00-3:00 pm	<p>Session 3: The impact of social determinants of health on outcomes</p> <ul style="list-style-type: none"> 1:00 Helen Ma, M.D. UC Irvine; A Long Beach Healthcare System in Long Beach, CA <i>Veteran's Health: The Connection Between Military Exposure and Lymphoma</i> 1:15 Alison Walker, M.D. Moffit Cancer Center, Tampa, FL <i>Disparities in AML survival for patients in medically underserved areas</i> 1:30 Theresa Keegan, Ph.D. University of California Davis School of Medicine, Sacramento, CA <i>Sociodemographic disparities in survivorship of Hodgkin's lymphoma patients</i> 1:45 Oreofe Odejide, M.D. Dana Farber Cancer Institute, Boston, MA <i>Health insurance and end-of-life care for people with hematologic malignancies</i> 2:00 Wellington Fernandes da Silva, M.D. Instituto do Cancer do Estado de São Paulo (ICESP), Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil <i>Management and outcomes of ALL in resource-constrained settings</i> 2:15 Discussion leader: Warren Fingrut, M.D. The University of Texas MD Anderson Cancer Center (45 min call to action-discussion)
3:00 -3:25 pm	Coffee Break
3:20-3:50 pm	<p>Keynote:</p> <ul style="list-style-type: none"> 3:20 Elisa Weiss, Ph.D. Sr. Vice President of Education, Services & Health Research, The Leukemia & Lymphoma Society <i>No Magic Bullet: A Multi-Pronged Approach to Increasing Equitable Access to Cancer Clinical Trials</i>
3:50-5:00 pm	<p>Session 4: Developing strategies to increase community representation in clinical enrollment</p> <ul style="list-style-type: none"> 3:50 Shalini Hede, Pharm.D. Medical Affairs Executive Director, Genentech; Hillsborough, NJ <i>Five Data-Informed Principles for Advancing Inclusive Research (AIR) in Clinical Trials</i> 4:05 Victor Gonzalez / Gina Aracena Lymphoma Research Foundation <i>Health Equity/ Spanish Language Navigation Project</i> 4:15 Mark Fiala, Ph.D. Washington University School of Medicine, St. Louis, MO <i>Use of patient portals for clinical trial recruitment</i>

<ul style="list-style-type: none"> 4:25 	<p>Nina Logan, M.D. Senior Director, Research & Clinical Programs, Leukemia & Lymphoma Society: IMPACT Program</p> <p>Enrique Diaz, M.D. University of Texas Health Science Center, San Antonio, TX</p> <p>Discussion leader: Oscar Lahoud, M.D. New York University Langone Hospital, Brooklyn, NY <i>(45 min call to action-discussion)</i></p>
5:10 -5:45	<p>Patient Advocacy Session</p> <p>Ms. Idatiu Diallo Lymphoma Survivor- NYU Langone</p> <p>Mr. Jonathan Guerrero_ Patient Advocate Lymphoma survivor & LLS Patient navigator</p> <p>Discussion Leader: Luis Malpica, M.D. The University of Texas MD Anderson Cancer Center</p>
5:45-7:45pm	Poster Session and Happy Hour

Day 2 - Saturday, June 7, 2025

8:00- 8:30 am	Registration and Breakfast
8:30- 8:30 am	<i>Session 5: Prognostic and therapeutic implications of the molecular landscape- Part B</i>
<ul style="list-style-type: none"> 8:30 	<p>Jatinder Lamba, Ph.D. University of Florida College of Pharmacy, Gainesville, FL <i>Pharmacogenetic based personalization to mitigate racial disparities in leukemia and other blood cancer outcomes</i></p>
<ul style="list-style-type: none"> 8:45 	<p>H. Leighton Grimes, Ph.D. Cincinnati Children's, Hospital, Cincinnati, OH <i>A genetic-genomics dissection of ancestry associated outcomes in acute myeloid leukemia.</i></p>
<ul style="list-style-type: none"> 9:00 	<p>Lawrence Boise, Ph.D. Emory University School of Medicine, Atlanta, GA <i>Defining the landscape of structural alterations in African American multiple myeloma</i></p>
<ul style="list-style-type: none"> 9:15 	<p>Nancy Gillis-Johnson, Pharm.D.; Ph.D. Moffit Cancer Center, Tampa, FL <i>Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma</i></p>
<ul style="list-style-type: none"> 9:30 	<p>Discussion leader: Monica Guzman, Ph.D. Weill Cornell Medicine <i>(45 min call to action-discussion)</i></p>
10:15 -10:35 am	Coffee Break

10:35- 12:00 pm	<p>Session 6: The burden of lymphoproliferative disorders in Latin America & lower-middle-income countries</p> <ul style="list-style-type: none"> • 10:35 Carlos Chiattonne, M.D. Faculdade de Ciências Médicas da Santa Casa de São Paulo, Brazil <i>Treatment and outcomes of lymphoma patients in Brazil and LATAM</i> • 10:50 Cristobal Frutos M.D. Instituto de Previsión Social, Asuncion, Paraguay <i>Stem cell Transplants in Latin America: mapping, sequencing and treating myeloid malignancies</i> • 11:05 Robert Baiocchi, M.D. Ohio State University Comprehensive Cancer Center, Columbus, OH <i>EBV+ lymphomas in Ethiopia</i> • 11:20 Daniel Enriquez- Vera, MD. Kagoshima University, Sakuragaoka, Kagoshima, Japan <i>HTLV-1 ancestry and ATLL in Japan and LATAM</i> • 11:35 Discussion leader: Guilherme Duffles Amarante, M.D. Faculdade de Ciências Médicas da Santa Casa de São Paulo, Brazil (25 min call to action-discussion)
12:00 pm	Lunch
1:15-1:35 pm	<p>Session 7 Project Highlight: The Leukemia & Lymphoma Society's Specialized Center of Research (SCOR) program</p> <p>Jean Koff, M.D., M.S. Emory Winship Cancer Institute, Atlanta, GA <i>Translating molecular profiles into treatment approaches to target disparities in lymphoma</i></p>
1:35 – 2:50 pm	<p>Session 8: Developing a funding strategy to address disparities</p> <ul style="list-style-type: none"> • 1:35 pm Meghan Gutierrez Chief Executive Officer, Lymphoma Research Foundation • 1:45 pm Lore Gruenbaum, Ph.D. Sr. Vice President and Chief Scientific Officer, The Leukemia & Lymphoma Society • 1:55 pm Patricia Frustace Senior Director, Awards & Diversity Programs, American Society of Hematology • 2:05 pm Deirdra R. Terrell, Ph.D. University of Oklahoma Health Sciences Center; ASH MRI Program • 2:15 pm Discussion leader: Christopher Flowers, M.D., M.S., FASCO The University of Texas, MD Anderson Cancer Center (45 min call to action-discussion)
3:00 -3:15 pm	Coffee Break
3:15 – 4:15 pm	<p>Keynote:</p> <p>Kelou Fox, Ph.D.</p>

	University of California San Diego, San Diego, CA <i>Robin Hood Genomics: Sequencing for Sovereignty</i>
4:15 -4:20 pm	Closing Remarks
4:20 pm	Adjourn